Tech Company Inital Public Offerings
Evelo Biosciences IPO
Evelo Biosciences, based in West Cambridge, debuted as a public company on 5/8/2018.
Transaction Overview
Company Name
Announced On
5/8/2018
Transaction Type
IPO
Amount
$85,000,000
Proceeds Purpose
$45.0 million to $50.0 million to fund proof of concept clinical trials in our inflammatory diseases programs; $25.0 million to $35.0 million to fund proof of concept clinical trials in our oncology programs;$35.0 million to $45.0 million to invest in our platform and to advance additional preclinical development activities; the remainder to fund working capital, capital expenditures and other general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
620 Memorial Dr. 200
West Cambridge, MA 02139
USA
West Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Evelo Biosciences (Nasdaq: EVLO) is dedicated to improving the lives of patients globally through the development of a new modality of medicines -- monoclonal microbials. Monoclonal microbials are orally delivered medicines that modulate systemic immunology and biology through direct interactions with human cells in the gut.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Simba Gill
Chief Medical Officer
Duncan McHale
Chief Scientific Officer
Mark Bodmer
VP - Bus. Development
Kareem Reda
VP - Manufacturing
Chun Zhang
Browse more venture capital transactions:
Prev: 5/8/2018: Learning Machine venture capital transaction
Next: 5/8/2018: Miovision venture capital transaction
Share this article
Where The Data Comes From
We do our best to record all VC transactions involving tech companies. VC investment data records reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs